Modified-release drug delivery systems are designed to optimize the therapeutic effect of drugs by minimizing side effects, reducing the dosage required, and controlling drug release to align with pharmacokinetic and pharmacodynamic needs. The system depends on two key factors: the drug's release from the formulation and its movement through the body to the target site. Unlike conventional dosage forms, where absorption is the limiting step, the rate of drug release is the key determinant in modified systems.
Drug properties play a critical role in their suitability for modified release. Low molecular weight drugs like pentoxifylline are absorbed faster, making them suitable candidates. Drugs with good aqueous solubility above 0.1 mg/mL are ideal for oral formulations, while poorly soluble drugs are better suited for parenteral delivery. Lipophilic drugs with high partition coefficients exhibit enhanced absorption and tissue distribution. Stability is also crucial; for instance, nitroglycerine, which is unstable in the gastrointestinal tract, is better administered transdermally.
The route of administration must consider drug properties, dose size, and desired duration. Oral delivery is effective for drugs like propranolol that maintain consistent absorption, while transdermal and intramuscular routes suit drugs with extensive first-pass metabolism or requiring prolonged action, such as nitroglycerin and depot formulations, respectively.
Pharmacokinetics further dictate design. Drugs with a half-life of 2–4 hours are ideal, as seen with propranolol. However, drugs with short half-lives, such as MAO inhibitors, require frequent dosing and may not be suitable. Pharmacodynamic factors, including dose size (typically <1 gram), therapeutic range, and plasma concentration-response relationship, also influence system design. Drugs with a narrow therapeutic index, such as those exhibiting toxicity near therapeutic levels, demand precise release control. Modified-release systems ensure sustained drug release, balancing pharmacological needs with patient safety.
Modified-release drug delivery systems optimize drug therapy by minimizing doses, reducing side effects, and ensuring efficient treatment.
These systems regulate drug release to align with the drug's absorption rate and therapeutic objective.
Drugs having low molecular weights, aqueous solubility above 0.1 mg/mL, and balanced lipophilicity perform best.
Stability is crucial, as drugs unstable in the gastrointestinal tract may require alternative routes like transdermal delivery.
Consistent absorption is vital for effective administration. Oral routes suit stable drugs with doses under 1000 mg, while intramuscular and transdermal routes support extended action or bypass first-pass metabolism.
Pharmacokinetic factors like efficient absorption, an elimination half-life typically between 2 and 4 hours, and consistent metabolism are essential for controlled delivery.
Drugs must also have appropriate pharmacodynamics, including a dose under 1g, a wide therapeutic range, and predictable concentration-response relationships.
繁體中文
